Crohn’s Disease Therapeutics Market By Treatment Type (Biologic Therapies {Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Integrin Inhibitors}, Small Molecule Drugs {Janus Kinase inhibitors, Sphingosine-1-Phosphate modulators}, Conventional Therapies {Corticosteroids, Aminosalicylates, Immunomodulators}, Emerging Therapies {Cell-based therapies, Microbiome-modulating agents, RNA-based therapies}, Others), By Route of Administration (Oral, Injectable, {Subcutaneous, Intravenous}), By Disease Severity (Mild to Moderate Crohn’s Disease, Moderate to Severe Crohn’s Disease, Refractory or Complex Cases), By End-User  (Hospitals, Clinics, Homecare), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Crohn’s Disease Therapeutics market accounted for USD 13.72 Billion in 2024 and is expected to reach USD 19.4 Billion by 2035, growing at a CAGR of around 3.2% between 2025 and 2035. The Crohn’s Disease therapeutics market is dedicated to the production and distribution of medicines for Crohn’s disease, a type of inflammatory bowel disease that is chronic. This market comprises therapies like biologics, including TNF inhibitors, IL-12/23 inhibitors, immunosuppressive agents, corticosteroids, and antibiotics used to decrease inflammation, assuage symptoms, and reduce the risk of relapse.

With the global increase in Crohn's disease incidence, the market is steadily expanding through medication research, tailored medicine, and promotion. It comprises pharmacological and non-pharmacological treatments, and it involves hefty spending on clinical trials and new inventions.

Report Scope:

Market Dynamics

Increasing cases globally drive demand for effective therapeutics and better treatment options.

Several driving forces have contributed to the growth of the Crohn’s Disease therapeutics market. Crohn's disease is becoming more common around the world, and there is a greater need among patients for effective therapies for the ailment as a result of early detection and increasing awareness. Due to advancements in knowledge concerning the pathogenesis of the ailment, newer and more effective biologic and immunotherapeutic options are available in disease management. One of the key drivers is the move toward customized therapy, which is driven by the genetic and molecular characteristics of target diseases. Rising healthcare costs, ongoing research, and understanding in this field contribute to the growing number of treatment options. The American College of Gastroenterology estimates that 3 million Americans suffer from inflammatory bowel illness, like Crohn's disease, highlighting the enormous market and medical need for effective medicines.

The development of targeted biologics and immunomodulators significantly improves treatment outcomes.

The Crohn’s disease therapeutics market has drivers such as the rising incidence of the illness across the world and improved accuracy of the treatment. One of the key trends of development in this region is the increasing popularity of first-in-class biologics and immunomodulators, which often enable individualized therapy. TNF inhibitors and IL 12/23 inhibitors are two medications that have altered treatment by controlling inflammation and bringing patients into remission. Furthermore, there has been an increase in awareness of the condition, advanced diagnostics, and increasing patients' access to healthcare technologies, all of which have contributed to the market's expansion.

Higher research expenses on new end-point therapies, including stem cell transplantation and gene therapy, are also driving the market growth. The long-term increase in demand for novel, minimally invasive, personalized treatment plans and the ongoing focus on patients' quality of life will drive up Crohn's disease therapeutic demand even further.

Biologics and other therapies are expensive, limiting affordability for many patients.

The high cost of biologics and other advanced therapy alternatives is a significant hurdle in the Crohn's Disease therapeutics market. Anti-TNF-R and monoclonal antibodies have been used as first-line treatments for moderate to severe cases, but they are expensive, making them out of reach for middle-aged people in low-income nations. These costs influence the cost of therapies, fabrication costs, the complex manufacturing process, and subsequent treatment regimens, making therapies expensive for both patients and healthcare facilities. It may place financial limits on acceptable therapies, limiting the intended quality of health results for some people. Further, insufficient insurance legislation and reimbursement methods in many countries impede market expansion, particularly by failing to provide universal insurance coverage to all patients.

The development of cost-effective biosimilars can improve accessibility to treatments

The increase in affordability of biosimilars is a massive unmet need in treatment options for patients with Crohn’s Disease and presents a promising opportunity for the market. TNF inhibitors such as infliximab and adalimumab have proved effective in dealing with Crohn’s Disease, and biosimilars are more cost-effective compared to original biologic agents. The continuous rise of biosimilar use may help manage existing treatment costs, particularly in outlawed regions with high operational costs. It lowers patient costs while increasing therapy access in a variety of settings, notably in developing countries. As regulatory systems for biosimilar pharmaceuticals remain in place, commercial opportunities emerge, patients benefit from future improvements in their quality of life and disease treatment is maximized throughout time. Further, biosimilars may bring a competitive advantage and innovations that can speed up the progress of developing new therapies for Crohn’s Disease.

Tailoring therapies based on genetic and immune profiles offers significant growth potential

The Crohn’s Disease therapeutics market remains sufficiently large for additional growth by personalizing its courses and therapies to patients’ genetic and immune responses. The focus of the therapeutic strategy promotes nothing but the delivery of a medication that directly attacks the cause of the disease, thus resulting in better outcomes with few side effects. Increased selectiveness of biomarkers for genetic disorders and immune patterns promotes enhanced prognosis and better adjustment of the treatment regimen to meet individual needs.

However, this focus on personalized treatment could improve the overall conditions and the frequency of repeated bouts. Furthermore, rising knowledge of Crohn's disease heterogeneity has created opportunities for the development of innovative drugs, elevating the rank of highly imaginative treatment. Since the introduction of biologics and tiny compounds capable of selectively acting on pathways, the market growth potential has been significant. Increased healthcare spending at the molecular level, such as personalized medication and gene pool expansion via diagnostic technologies, will assist in driving growth.

Industry Experts Opinion

"Disruptive symptoms of Crohn's disease, such as bowel urgency, can interfere with all aspects of life, leaving many people searching for treatments that can help them fully participate in the things that they enjoy.”

• Mark Genovese-Lilly immunology development senior vice-president

Segment Analysis

Based on treatment type, the Crohn’s Disease Therapeutic Market is classified into Biologic Therapies, Small Molecule Drugs, Conventional Therapies, Emerging Therapies, and Others. In the Crohn’s Disease therapeutics market, biologic therapies are the largest and dominate the market. This family of medications includes TNF inhibitors (Infliximab, Adalimumab), integrin inhibitors, and interleukin inhibitors, which provide focused therapy to cure diseases by inhibiting specific immune pathways that cause inflammation. Biologics have higher remission and control rates compared to conventional therapies for inflammatory bowel disease. The increased prescriptions due to the development of targeted treatments in medicine and enhanced results suggest that biologics have become essential for treating Crohn’s disease even though they are more expensive.

Based on disease severity, the Crohn’s Disease Therapeutic Market is classified into Mild to Moderate Crohn’s Disease, Moderate to Severe Crohn’s Disease, and Refractory or Complex Cases. The moderate to severe Crohn's Disease category is the largest in the Crohn's Disease Therapeutics market. This is because individuals with Crohn's disease and its consequences, including fistulas, strictures, and abscesses, require additional clinical attention. Patients with disorders that require biological therapy, such as TNF inhibitors, IL-12/23 inhibitors, and JAK inhibitors, are driving market growth. Moreover, the rise in the number of cases reaching the middle/severe level is an essential problem to address, especially in this department, because people with such disorders require expert treatment.

Based on Route of Administration, the Crohn’s Disease Therapeutic Market is classified into Oral and Injectable. The injectable drug segment is the largest and most important segment in the Crohn’s Disease therapeutics market. This is due to the rising preference for biologic therapies such as anti-TNF drugs, infliximab, and adalimumab, as well as integrin inhibitors, which are provided systemically via injection or infusion. These biologics are well-known for their efficacy in the treatment of inflammation and, more specifically, moderate to severe Crohn's disease. The peel-in technique provides a faster and longer-acting solution than oral medications, some of which are ineffective in patients, and instantly injectable formulations are market leaders.

Regional Analysis

The North American Crohn's disease therapeutics market is leading, as is the availability of treatment options and knowledge of the condition. The United States is the region's largest market due to its patient population and the availability of developed healthcare facilities. Anti-TNF, IL inhibitors, and anti-integrin drugs remain the primary therapies, with fresh targeted biologics emerging in the market more frequently. Individual approaches, as well as segments like biosimilars, impact market potential. Further, current research, public policies, and advanced detection methods are perhaps more likely to boost treatment outcomes and related market features. The sector is projected to expand in the next years as people demand better and cheaper therapies.

The Asia-Pacific Crohn's Disease therapeutics market is developing due to factors such as increased awareness, improved diagnostic techniques, and an increase in the incidence of inflammatory bowel illnesses. It will do so specifically in nations such as Japan, China, India, and South Korea, where there is a growing need for healthcare and better access to therapies.

Biologic medicines, particularly TNF inhibitors and IL-12/23 inhibitors, are increasingly recommended since they have demonstrated efficacy in severe patients. Furthermore, rising demand for customized medicine and advancements in biosimilars impact the market's position. However, several constraints, such as disparities in care facilities and treatment prices and limited availability in rural areas, present barriers to the expansion of numerous markets in some nations. However, further impediments to the industry's continuous expansion exist; it is likely to grow as new pharmaceutical alternatives enter the market and healthcare systems adapt in the future.

Competitive Landscape

The Crohn's disease therapeutics market is dominated by major firms such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceuticals, Pfizer Inc., Eli Lilly and Company, Amgen Inc., and Bristol-Myers Squibb. As of now, AbbVie's Humira and Takeda's Entyvio are significant biologic medicines recommended generally in the treatment of IBDs, and AbbVie is already developing its second-generation medication, Rinvoq, for use in IBDs. Pfizer's Xeljanz and Eli Lilly's Mirikizumab have recently achieved success, with Mirikizumab displaying outstanding performance in Phase II clinical trials for Crohn's disease.

Alternative competitors include Amgen's Taltz and Bristol-Myers Squibb's Zeposia, both of which seek to occupy distinct inflammation-calming receptors. Oral biologics and other immunomodulators are among the new paths in development, and the business is becoming more competitive as companies attempt to capitalize on patients' desire for newer, easier, and better solutions.

Crohn’s Disease Therapeutics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In June 2024, AbbVie bought biotechnology firm Celsius Therapeutics for USD 250 million. The company is currently working on therapies for inflammatory bowel disease (IBD). The key to this acquisition is Celsius’ drug CEL383 has the potential to become the first of its kind for IBD patients. CEL383, has the potential to impact more patients as AbbVie aims to get more patients into remission.
• In June 2024, Johnson & Johnson applied for the FDA approval of TREMFYA for the Crohn’s disease treatment. This drug is already approved for use in patients with psoriasis and psoriatic arthritis. The outcome of the trials demonstrated that TREMFYA was successful in managing Crohn’s disease symptoms and might offer new treatment method for patients

Report Coverage:

By Treatment Type

• Biologic Therapies
  • Tumour Necrosis Factor (TNF) Inhibitors
  • Interleukin Inhibitors
  • Integrin Inhibitors
• Small Molecule Drugs
  • Janus Kinase inhibitors
  • Sphingosine-1-Phosphate modulators
• Conventional Therapies
  • Corticosteroids
  • Amino salicylates
  • Immunomodulators
• Emerging Therapies
  • Cell-based therapies
  • Microbiome-modulating agents
  • RNA-based therapies
• Others

By Route of Administration

• Oral
• Injectable
  • Subcutaneous
  • Intravenous

 By Disease Severity

• Mild to Moderate Crohn’s Disease
• Moderate to Severe Crohn’s Disease
• Refractory or Complex Cases

By End-User

• Hospitals
• Clinics
• Homecare

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• AbbVie Inc.
• Johnson & Johnson
• Takeda Pharmaceuticals
• Pfizer Inc.
• Eli Lilly and Company
• Amgen Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• UCB S.A.
• Biogen Inc.
• Celgene Corporation
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Samsung Bioepis

Frequently Asked Questions (FAQs)